India, Oct. 23 -- ORIC Pharmaceuticals (ORIC) presented clinical data for enozertinib, an investigational EGFR inhibitor, in patients with previously untreated non-small cell lung cancer (NSCLC) carry... Read More
India, Oct. 23 -- The University of Michigan released a report on Friday showing consumer sentiment in the U.S. deteriorated by far less than previously estimated in the month of October. The report ... Read More
India, Oct. 23 -- Friday, Munich Re (0KFE.L,MUV2.DE) announced its preliminary financial results for the third quarter, expecting a net profit of about 1.7 billion euros, exceeding the analysts' conse... Read More
India, Oct. 23 -- Friday, Ascom Holding AG (ASCN.SW) announced the completion of share capital reduction following the share buyback. Under the program, Ascom Holding AG repurchased 3 million registe... Read More
India, Oct. 23 -- Cumberland Pharmaceuticals Inc. (CPIX) reported results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc), with the study support... Read More
India, Oct. 23 -- China Resources Building Materials Technology Holdings Ltd. (1313.HK,CARCY) on Friday announced a turn to loss for the third quarter and first nine months of fiscal 2026 compared to ... Read More
India, Oct. 23 -- Cryptocurrencies are trading on a mixed note on Friday morning even as markets assessed the geopolitical situation in the Middle East, the outlook on the artificial intelligence trad... Read More
India, Oct. 23 -- Integrated payments company American Express Co. (AXP) reported Friday a profit for the third quarter that increased 27 percent from last year, reflecting higher net interest income ... Read More
India, Oct. 23 -- Friday, Bolt Biotherapeutics, Inc. (BOLT) announced its acquisition of Prana Therapies, Inc. through a stock-for-stock transaction aimed at advancing Prana's pipeline of half-life-ex... Read More
India, Oct. 23 -- AbbVie (ABBV) announced that the U.S. Food and Drug Administration approved a subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) for adults with moderately to severely ac... Read More